HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
KCNK10
potassium two pore domain channel subfamily K member 10
Chromosome 14 · 14q31.3
NCBI Gene: 54207Ensembl: ENSG00000100433.17HGNC: HGNC:6273UniProt: P57789
28PubMed Papers
20Diseases
5Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Ion ChannelTransporter
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
cellular response to arachidonatepotassium ion leak channel activitymechanosensitive potassium channel activityoutward rectifier potassium channel activityCOVID-19acute respiratory distress syndromecoronary artery diseasephobic disorder
✦AI Summary

KCNK10 (TREK-2) encodes a two-pore domain potassium channel that functions as a voltage-dependent outward rectifier and leak channel, playing crucial roles in neuronal excitability and pain modulation. The channel exhibits complex gating mechanisms, converting from voltage-dependent to voltage-independent 'leak' conductance upon stimulation by mechanical stretch, acidic pH, heat, and lipids 1. KCNK10 forms both homodimers and heterodimers with other K2P channels, creating functional channels with distinct regulatory properties. In nociceptive neurons, TREK-2 activation by PD-L1 induces hyperpolarization and inhibits pain transmission 2. The channel shows significant expression in the central nervous system, with alternative splice variants contributing to functional diversity 3. Disease relevance includes upregulation in temporal lobe epilepsy, where increased KCNK10 expression may serve a neuroprotective function 4, and expression in ovarian cancer where modulators affect cell proliferation and apoptosis 5. Genetic variants in KCNK10 have been associated with cardiac electrical activity parameters in HIV-positive individuals 6. The channel's polymodal regulation and role in cellular excitability make it a potential therapeutic target for pain, epilepsy, and cancer treatment.

Sources cited
1
TREK-2 exhibits voltage-dependent and leak conductance modes with gating controlled by mechanical stretch, pH, heat, and lipids
PMID: 38821927
2
PD-L1 activation of TREK-2 in nociceptive neurons causes hyperpolarization and pain inhibition
PMID: 28530662
3
TREK-2 has alternative splice variants with different functional properties and CNS expression patterns
PMID: 21821104
4
KCNK10/TREK-2 is upregulated in temporal lobe epilepsy and may serve neuroprotective functions
PMID: 27609046
5
TREK-1 and TREK-2 are expressed in ovarian cancer and normal ovaries, with modulators affecting cell proliferation and apoptosis
PMID: 23479219
6
KCNK10 genetic variants are associated with ECG parameters in HIV-positive individuals
PMID: 37418550
Disease Associationsⓘ20
COVID-19Open Targets
0.36Weak
acute respiratory distress syndromeOpen Targets
0.35Weak
coronary artery diseaseOpen Targets
0.33Weak
phobic disorderOpen Targets
0.32Weak
respiratory failureOpen Targets
0.32Weak
joint diseaseOpen Targets
0.32Weak
hypertrophic cardiomyopathyOpen Targets
0.31Weak
cancerOpen Targets
0.31Weak
alcohol drinkingOpen Targets
0.29Weak
ischemia reperfusion injuryOpen Targets
0.27Weak
crystal arthropathyOpen Targets
0.27Weak
diabetes mellitusOpen Targets
0.26Weak
brain aneurysmOpen Targets
0.26Weak
cerebral arterial diseaseOpen Targets
0.26Weak
esophageal cancerOpen Targets
0.26Weak
fluoride poisoningOpen Targets
0.26Weak
severe acute respiratory syndromeOpen Targets
0.26Weak
chondromalaciaOpen Targets
0.25Weak
protozoa infectious diseaseOpen Targets
0.25Weak
morbid obesityOpen Targets
0.18Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets5
DESFLURANEApproved
Potassium channel subfamily K member 10 opener
ENFLURANEApproved
Potassium channel subfamily K member 10 opener
HALOTHANEApproved
Potassium channel subfamily K member 10 opener
ISOFLURANEApproved
Potassium channel subfamily K member 2 opener
SEVOFLURANEApproved
Glycine receptor (alpha-1/beta) positive modulator
Related Genes
LRRC52Shared pathway100%LRRC26Shared pathway100%LRRC55Shared pathway100%LRRC38Shared pathway100%KCNK12Shared pathway100%KCNK2Protein interaction97%
Tissue Expression6 tissues
Brain
100%
Bone Marrow
33%
Heart
1%
Liver
0%
Ovary
0%
Lung
0%
Gene Interaction Network
Click a node to explore
KCNK10LRRC52LRRC26LRRC55LRRC38KCNK12KCNK2
PROTEIN STRUCTURE
Preparing viewer…
PDB8QZ3 · 2.40 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.69LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.49 [0.35–0.69]
RankingsWhere KCNK10 stands among ~20K protein-coding genes
  • #12,370of 20,598
    Most Researched28
  • #331of 1,025
    FDA-Approved Drug Targets5
  • #5,267of 17,882
    Most Constrained (LOEUF)0.69
Genes detectedKCNK10
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Integrative RNA profiling of TBEV-infected neurons and astrocytes reveals potential pathogenic effectors.
PMID: 35685361
Comput Struct Biotechnol J · 2022
1.00
2
PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1.
PMID: 28530662
Nat Neurosci · 2017
0.90
3
Identification and characterization of alternative splice variants of the mouse Trek2/Kcnk10 gene.
PMID: 21821104
Neuroscience · 2011
0.80
4
Extracellular modulation of TREK-2 activity with nanobodies provides insight into the mechanisms of K2P channel regulation.
PMID: 38755204
Nat Commun · 2024
0.70
5
Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer.
PMID: 23479219
Clin Transl Oncol · 2013
0.60